# GIMEMA

Source: https://onco.cc/companies/gimema/  
OnCo record `gimema` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Italy's adult haematology trials group, famous for making acute promyelocytic leukaemia curable without chemotherapy and for chemotherapy-free Philadelphia-positive ALL.

## Summary

Founded in 1982, GIMEMA coordinates more than 100 Italian haematology centres from Rome. With the German AMLSG it ran APL0406, which showed all-trans retinoic acid plus arsenic trioxide beats chemotherapy in low-to-intermediate risk acute promyelocytic leukaemia, and its LAL2116 D-ALBA trial showed dasatinib followed by blinatumomab can induce deep molecular responses in Ph-positive ALL without cytotoxic chemotherapy. GIMEMA also runs CML, CLL, myeloma and MDS trials and a central laboratory network for molecular monitoring. Its quality-of-life working party pioneered patient-reported outcomes in haematology trials.

## Fields

- Kind: Company
- Last checked: 2026-09-09
- Also known as: Gruppo Italiano Malattie EMatologiche dell'Adulto; Italian Group for Adult Hematologic Diseases
- Tags: cooperative-group
- HQ: Rome
- Type: cooperative-group
- Website: https://www.gimema.it

## Notes

- APL0406 (ATRA-arsenic in APL)
- D-ALBA (chemo-free Ph+ ALL)
- CML and CLL trials
- Central molecular monitoring laboratories

## Sources

- GIMEMA: https://www.gimema.it

## Connected records

- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/), [Imatinib](https://onco.cc/drugs/imatinib/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- companies: [HOVON](https://onco.cc/companies/hovon/)
- terms: [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- trials: [D-ALBA (GIMEMA LAL2116)](https://onco.cc/trials/d-alba/)
- people: [Antonio Cuneo](https://onco.cc/people/antonio-cuneo/), [Marco Vignetti](https://onco.cc/people/marco-vignetti/)
- institutions: [European Hematology Association](https://onco.cc/institutions/eha/), [Fondazione AIRC per la ricerca sul cancro](https://onco.cc/institutions/airc/)

---
JSON: https://onco.cc/api/v1/entities/gimema.json